The aggressive clinical courses of Hodgkin lymphoma primarily diagnosed as methotrexate-induced non-specific lymphoproliferative disorder in patients with rheumatoid arthritis

Access this Article

Search this Article

Author(s)

    • Okuyama Ayumi
    • Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University
    • Watanabe Reiko
    • Department of Hematology, Saitama Medical Center, Saitama Medical University
    • Amano Koichi
    • Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University
    • Tamaru Jun-ichi
    • Department of Pathology, Saitama Medical Center, Saitama Medical University
    • Kizaki Masahiro
    • Department of Hematology, Saitama Medical Center, Saitama Medical University
    • Tanaka Yuka
    • Department of Hematology, Saitama Medical Center, Saitama Medical University
    • Kimura Yuta
    • Department of Hematology, Saitama Medical Center, Saitama Medical University
    • Tomikawa Tatsuki
    • Department of Hematology, Saitama Medical Center, Saitama Medical University
    • Anan-Nemoto Tomoe
    • Department of Hematology, Saitama Medical Center, Saitama Medical University
    • Momose Shuju
    • Department of Pathology, Saitama Medical Center, Saitama Medical University
    • Higashi Morihiro
    • Department of Pathology, Saitama Medical Center, Saitama Medical University

Abstract

<p>Recently, attention has been focused on methotrexate-induced lymphoproliferative disease (MTX-LPD), and atypical phenotypes are occasionally documented. We encountered two patients with rheumatoid arthritis (RA) who were diagnosed with non-specific LPD (LPD-nos). Biopsy samples were not obtained during the initial examination when the LPD development was discovered, and the patients achieved a complete response after MTX cessation (case 1) or steroid pulse therapy (case 2). However, the tumors flared up 1.5 years later, and LPD-nos was determined following biopsies of the lymph node (LN, case 1) and liver (case 2). Prednisolone was subsequently administered instead of chemotherapy; however, multiple masses, including in the spine (case 1), and severe icterus with liver dysfunction (case 2) were exacerbated within a few months. Although the re-biopsy of LN proved the presence of HL and radiation followed by aggressive chemotherapy rescued the patient (case 1), the superficially accessible biopsy site was not found, and autopsy finally revealed HL (case 2). In both cases, the underlying pathogenesis along with the B symptoms and laboratory abnormalities suggested MTX-LPD, HL in particular. Therefore, even if the pathological diagnosis does not confirm the specific LPD subtype, the administration of aggressive chemotherapy should be considered if the LPD activity flares severely.</p>

Journal

  • Journal of Clinical and Experimental Hematopathology

    Journal of Clinical and Experimental Hematopathology 56(3), 165-169, 2017

    The Japanese Society for Lymphoreticular Tissue Research

Codes

  • NII Article ID (NAID)
    130005465213
  • Text Lang
    ENG
  • ISSN
    1346-4280
  • Data Source
    J-STAGE 
Page Top